163 related articles for article (PubMed ID: 37485727)
61. Rivastigmine for cognitive impairment after spontaneous subarachnoid haemorrhage: a pilot study.
Wong GK; Wong R; Mok V; Wong A; Fan D; Leung G; Chan A; Poon WS
J Clin Pharm Ther; 2009 Dec; 34(6):657-63. PubMed ID: 20175798
[TBL] [Abstract][Full Text] [Related]
62. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease.
Articus K; Baier M; Tracik F; Kühn F; Preuss UW; Kurz A
Int J Clin Pract; 2011 Jul; 65(7):790-6. PubMed ID: 21645184
[TBL] [Abstract][Full Text] [Related]
63. Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer's disease.
Marin D; Amaya K; Casciano R; Puder KL; Casciano J; Chang S; Snyder EH; Cheng I; Cuccia AJ
Int Psychogeriatr; 2003 Dec; 15(4):385-98. PubMed ID: 15000418
[TBL] [Abstract][Full Text] [Related]
64. Effect of rivastigmine on regional cerebral blood flow in Alzheimer's disease.
Cerci SS; Tamam Y; Kaya H; Yildiz M; Arslan S
Adv Ther; 2007; 24(3):611-21. PubMed ID: 17660172
[TBL] [Abstract][Full Text] [Related]
65. Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease.
Cummings JL; Farlow MR; Meng X; Tekin S; Olin JT
Clin Drug Investig; 2010; 30(1):41-9. PubMed ID: 19995097
[TBL] [Abstract][Full Text] [Related]
66. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
[TBL] [Abstract][Full Text] [Related]
67. Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: a naturalistic prospective study in Alzheimer's disease.
Cagnin A; Cester A; Costa B; Ermani M; Gabelli C; Gambina G;
Neurol Sci; 2015 Mar; 36(3):457-63. PubMed ID: 25394739
[TBL] [Abstract][Full Text] [Related]
68. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study.
Ballard C; Sauter M; Scheltens P; He Y; Barkhof F; van Straaten EC; van der Flier WM; Hsu C; Wu S; Lane R
Curr Med Res Opin; 2008 Sep; 24(9):2561-74. PubMed ID: 18674411
[TBL] [Abstract][Full Text] [Related]
69. Transdermal rivastigmine for HIV-associated cognitive impairment: A randomized pilot study.
Muñoz-Moreno JA; Prats A; Moltó J; Garolera M; Pérez-Álvarez N; Díez-Quevedo C; Miranda C; Fumaz CR; Ferrer MJ; Clotet B;
PLoS One; 2017; 12(8):e0182547. PubMed ID: 28854283
[TBL] [Abstract][Full Text] [Related]
70. Association between baseline cognitive impairment and postoperative delirium in elderly patients undergoing surgery for adult spinal deformity.
Adogwa O; Elsamadicy AA; Vuong VD; Fialkoff J; Cheng J; Karikari IO; Bagley CA
J Neurosurg Spine; 2018 Jan; 28(1):103-108. PubMed ID: 29125432
[TBL] [Abstract][Full Text] [Related]
71. Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine.
Hauber AB; Gnanasakthy A; Mauskopf JA
Clin Ther; 2000 Apr; 22(4):439-51. PubMed ID: 10823365
[TBL] [Abstract][Full Text] [Related]
72. Oral and Transdermal Rivastigmine for the Treatment of Anticholinergic Delirium: A Case Report.
Fratta KA; Ginder M; Haggerty DA
J Emerg Med; 2023 Oct; 65(4):e366-e368. PubMed ID: 37716903
[TBL] [Abstract][Full Text] [Related]
73. Cholinesterase inhibitor treatment in patients with delirium.
Opdam FL; Oleksik AM; Westendorp RG
Lancet; 2011 Mar; 377(9769):900-1; author reply 901. PubMed ID: 21397759
[No Abstract] [Full Text] [Related]
74. BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.
Chianella C; Gragnaniello D; Maisano Delser P; Visentini MF; Sette E; Tola MR; Barbujani G; Fuselli S
Eur J Clin Pharmacol; 2011 Nov; 67(11):1147-57. PubMed ID: 21630031
[TBL] [Abstract][Full Text] [Related]
75. Comparative Efficacy and Acceptability of Cholinesterase Inhibitors and Memantine Based on Dosage in Patients with Vascular Cognitive Impairment: A Network Meta-analysis.
Shi X; Ren G; Cui Y; Xu Z
Curr Alzheimer Res; 2022; 19(2):133-145. PubMed ID: 35048806
[TBL] [Abstract][Full Text] [Related]
76. Cholinesterase inhibitor treatment in patients with delirium.
Frölich L; Förstl H
Lancet; 2011 Mar; 377(9769):899; author reply 901. PubMed ID: 21397755
[No Abstract] [Full Text] [Related]
77. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
López-Pousa S; Turon-Estrada A; Garre-Olmo J; Pericot-Nierga I; Lozano-Gallego M; Vilalta-Franch M; Hernández-Ferràndiz M; Morante-Muñoz V; Isern-Vila A; Gelada-Batlle E; Majó-Llopart J
Dement Geriatr Cogn Disord; 2005; 19(4):189-95. PubMed ID: 15677866
[TBL] [Abstract][Full Text] [Related]
78. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
Rodda J; Morgan S; Walker Z
Int Psychogeriatr; 2009 Oct; 21(5):813-24. PubMed ID: 19538824
[TBL] [Abstract][Full Text] [Related]
79. Penehyclidine hydrochloride on postoperatively cognitive function.
Hongyu X; Qingting W; Xiaoling S; Liwu Z; Ailing Y; Xin L
Med Hypotheses; 2019 Aug; 129():109246. PubMed ID: 31371081
[TBL] [Abstract][Full Text] [Related]
80. Cholinesterase inhibitor treatment in patients with delirium.
de Pont AC; van Geer MA; Schultz MJ
Lancet; 2011 Mar; 377(9769):899; author reply 901. PubMed ID: 21397757
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
